Skip to content

Assessing the effectiveness of topical peppermint cream and orally ingestible peppermint oxymel mouthwash on halitosis and vomiting of breast cancer patients during chemotherapy

A clinical trial to assess the effectiveness of antiemetic and anti-halitosis topical peppermint cream and orally ingestible peppermint oxymel mouthwash in breast cancer patients during chemotherapy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201219049763N1
Enrollment
225
Registered
2021-06-08
Start date
2021-06-20
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer patients treated with chemotherapy drugs. Malignant neoplasm of breast

Interventions

Intervention 1: Intervention group one: In addition to taking the anti-nausea and antiemetic drugs Aprepitant and Dexamethasone, patients use mint serpentine mouthwash.Its ingredients are 5% water, 5%

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: No history of nausea and vomiting for other reasons Full consciousness Literacy Complete satisfaction in participating in this project Breast cancer, ac4T4 chemotherapy regimen, taking anti-nausea and vomiting drugs Aprepitant and Dexamethasone No history of allergies Medicinal plants No history of respiratory diseases, asthma, diabetes and autoimmune diseases

Exclusion criteria

Exclusion criteria: Eliminate patients who use medications or treatments other than those prescribed during the study to reduce nausea and vomiting Patients who forget to use the product and mouthwash three or more times in a row

Design outcomes

Primary

MeasureTime frame
Nausea score in questionnaires. Timepoint: At the beginning of the study, every day based on the Daily questionnaire, every 14 days based on the Rhodes questionnaire. Method of measurement: Daily questionnaire and Rhodes questionnaire.;Halitosis scores on questionnaires. Timepoint: At the beginning of the study, every day based on the Daily questionnaire, every 14 days based on the Rhodes questionnaire. Method of measurement: Daily questionnaire and Rhodes questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Madjid Ansari

Iranian academic center for education culture and research

majidansari@acecr.ac.ir+98 21 8879 6208

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026